Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Enochian Biosciences, Inc. (ENOB)

1.19   0.02 (1.71%) 12-02 16:00
Open: 1.2 Pre. Close: 1.17
High: 1.3122 Low: 1.175
Volume: 161,387 Market Cap: 63(M)

Technical analysis

as of: 2022-12-02 4:22:27 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.07     One year: 2.51
Support: Support1: 1.15    Support2: 0.96
Resistance: Resistance1: 1.77    Resistance2: 2.15
Pivot: 1.65
Moving Average: MA(5): 1.41     MA(20): 1.7
MA(100): 2.11     MA(250): 4.5
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 1.5     %D(3): 3.3
RSI: RSI(14): 28.9
52-week: High: 11.64  Low: 1.15
Average Vol(K): 3-Month: 49 (K)  10-Days: 48 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ENOB ] has closed below the lower bollinger band by 2.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 28.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.32 - 1.32 1.32 - 1.33
Low: 1.16 - 1.17 1.17 - 1.17
Close: 1.17 - 1.19 1.19 - 1.2

Company Description

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Headline News

Wed, 30 Nov 2022
Enochian gets Nasdaq notice for delaying (NASDAQ:ENOB) - Seeking Alpha

Wed, 30 Nov 2022
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022 -

Wed, 09 Nov 2022
Cephasonics Announces New Integrated Application-Ready OEM Ultrasound Cart Systems - MedTech Dive

Thu, 20 Oct 2022
Investigation Alert UBER, CODX, ENOB, OM: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses? - GlobeNewswire

Mon, 26 Sep 2022
DEADLINE ALERT for ENOB, WEBR, and CVNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire

Thu, 22 Sep 2022
ENOB LAWSUIT ALERT: Levi & Korsinsky Notifies Enochian BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 53 (M)
Shares Float 17 (M)
% Held by Insiders 61.7 (%)
% Held by Institutions 7.2 (%)
Shares Short 1,410 (K)
Shares Short P.Month 1,430 (K)

Stock Financials

EPS -0.79
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.04
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -11.4
Return on Equity (ttm) -25.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.61
Qtrly Earnings Growth 0
Operating Cash Flow -26 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -1.51
PEG Ratio 0
Price to Book value 0.39
Price to Sales 0
Price to Cash Flow -2.46

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.